Case File
efta-efta01859140DOJ Data Set 10CorrespondenceEFTA Document EFTA01859140
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-efta01859140
Pages
0
Persons
0
Integrity
Loading PDF viewer...
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
From:
Sent
Wed 7113/2011 12:21:03 PM
Subject: Re: STN
i need more info.
On Wed, Jul 13, 2011 at 6:03 AM, <
wrote:
I am helping Chinese airport group for relationship reasons to get access to Stansted airport,
but I am quite sure they will not buy it. Value approx £ I billion,
The owner - Ferrovial from Spain - must sell and would now consider exclusivity.
Interesting for us?
Scc below:
Following our meeting in Madrid if you are interested in acquiring Stansted, here is, for your
convenience, a short summary of how Mr Meiras and Mr Villen described, very confidentially,
their position:
•
Stansted is no longer a strategic asset and Ferrovial is open to selling the asset even if the
regulator does not demand a disposal
•
Ferrovial is willing to entertain confidential and exclusive discussions with Hainan
regarding a potential sale. To do so Ferrovial proposes the following process:
1.
Hainan submits a non-binding indication of interest and a list of preliminary information
that would be requested. This is a simple letter and does not require providing a valuation
2.
Ferrovial and Hainan enter into a non-disclosure agreement
3.
Ferrovial provides Hainan confidential financial information, sufficient to value Stansted
4.
Hainan prepares and submits a non-binding offer including a valuation for the acquisition
of 100% ownership of Stansted
5.
Ferrovial, if Hainan's offer is sufficiently attractive, approaches its co-shareholders in
BAA and the BAA board with the proposal to conduct a formal, but confidential transaction
discussions with Hainan
6.
Standard transaction process
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
EFTA_R1_00258124
EFTA01859140
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA_R1_00258125
EFTA01859141
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
OtherUnknown
FEDWIRE PAYMENT DEBIT ADVICE
DOJ EFTA Data Set 10 document EFTA01273102
16p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.